OBJECTIVE: This post hoc analysis evaluated long-term efficacy and safety in patients with focal to bilateral tonic-clonic seizures (FBTCS) or generalized tonic-clonic seizures (GTCS) who entered open-label extension (OLEx) studies to receive long-term adjunctive perampanel. METHODS: Patients aged 12 years and older who completed phase II or III randomized, double-blind, placebo-controlled studies could enter an OLEx study, each comprising a blinded conversion period followed by an open-label maintenance period (32-424 weeks; maximum perampanel dose = 12 mg/d). Exposure, seizure outcomes, and treatment-emergent adverse events (TEAEs) were analyzed. RESULTS: Baseline characteristics were generally balanced between patients with FBTCS (n = 720) and GTCS (n = 138). Mean (standard deviation) cumulative duration of perampanel exposure was 102.3 (70.3) weeks (FBTCS) and 83.9 (38.4) weeks (GTCS). Retention rates were 50.0% for up to 4 years (FBTCS) and 49.2% for up to 2 years (GTCS). Across OLEx treatment durations, median reductions in seizure frequency per 28 days were 66.7% (FBTCS) and 80.6% (GTCS). Fifty percent and 75% responder and seizure-freedom rates were 59.5%, 45.3%, and 18.4%, respectively (FBTCS), and 72.5%, 51.5%, and 16.7%, respectively (GTCS). Efficacy was sustained for up to 4 years (FBTCS) and up to 3 years (GTCS), even when accounting for early dropouts. TEAE incidence was highest during Year 1 (FBTCS, 85.3%; GTCS, 86.2%); most common were dizziness and somnolence. During Year 1, serious TEAEs were reported in 81 (11.3%; FBTCS) and 10 (7.2%; GTCS) patients. TEAEs were consistent with the known safety profile of perampanel; no new safety signals were identified with long-term treatment. SIGNIFICANCE: This post hoc analysis suggests long-term (up to 4 years) adjunctive perampanel (up to 12 mg/d) is efficacious and well tolerated in patients (aged 12 years and older) with FBTCS or GTCS.

Brno Epilepsy Center and Central European Institute of Technology Masaryk University Brno Czech Republic

Department of Neurology Johns Hopkins University School of Medicine Baltimore Maryland USA

Eisai Inc Woodcliff Lake New Jersey USA

Eisai Ltd Hatfield UK

Formerly Eisai Inc Woodcliff Lake New Jersey USA

Idaho Comprehensive Epilepsy Center Boise Idaho USA

National Epilepsy Center Shizuoka Institute of Epilepsy and Neurological Disorders Shizuoka Japan

North Tohoku Epilepsy Center Minato Hospital Hachinohe Japan

See more in PubMed

Food and Drug Administration . Fycompa® prescribing information. May 2019. Available at: https://www.fycompa.com/‐/media/Files/Fycompa/Fycompa_Prescribing_Information.pdf. Accessed May 11, 2020.

European Medicines Agency . Fycompa® annex I: summary of product characteristics. April 2017. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/002434/WC500130815.pdf. Accessed May 11, 2020.

Krauss GL, Bar M, Biton V, et al. Tolerability and safety of perampanel: two randomized dose‐escalation studies. Acta Neurol Scand. 2012;125:8–15. PubMed

French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial‐onset seizures: randomized phase III study 304. Neurology. 2012;79:589–96. PubMed PMC

French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial‐onset seizures: results of randomized global phase III study 305. Epilepsia. 2013;54:117–25. PubMed

Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial‐onset seizures. Neurology. 2012;78:1408–15. PubMed

Nishida T, Lee SK, Inoue Y, et al. Adjunctive perampanel in partial‐onset seizures: Asia‐Pacific, randomized phase III study. Acta Neurol Scand. 2018;137:392–9. PubMed

French JA, Krauss GL, Wechsler RT, et al. Perampanel for tonic‐clonic seizures in idiopathic generalized epilepsy: a randomized trial. Neurology. 2015;85:950–7. PubMed PMC

Kwok CS, Johnson EL, Krauss GL. Comparing safety and efficacy of "third‐generation" antiepileptic drugs: long‐term extension and post‐marketing treatment. CNS Drugs. 2017;31:959–74. PubMed

Rektor I, Krauss GL, Bar M, et al. Perampanel Study 207: long‐term open‐label evaluation in patients with epilepsy. Acta Neurol Scand. 2012;126:263–9. PubMed

Krauss GL, Perucca E, Ben‐Menachem E, et al. Long‐term safety of perampanel and seizure outcomes in refractory partial‐onset seizures and secondarily generalized seizures: results from phase III extension study 307. Epilepsia. 2014;55:1058–68. PubMed PMC

ClinicalTrials.gov . A study with an open‐label extension phase to evaluate the efficacy and safety of perampanel (E2007) administered as an adjunctive therapy in subjects with refractory partial‐onset seizures. 2018. Available at: https://clinicaltrials.gov/ct2/show/NCT01618695. Accessed May 11, 2020.

ClinicalTrials.gov . A efficacy and safety study of adjunctive perampanel in primary generalized tonic clonic seizures. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01393743. Accessed May 11, 2020.

Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:522–30. PubMed

Asadi‐Pooya AA, Nikseresht A, Yaghoubi E, Nei M. Physical injuries in patients with epilepsy and their associated risk factors. Seizure. 2012;21:165–8. PubMed

Holst AG, Winkel BG, Risgaard B, et al. Epilepsy and risk of death and sudden unexpected death in the young: a nationwide study. Epilepsia. 2013;54:1613–20. PubMed

Thurman DJ, Hesdorffer DC, French JA. Sudden unexpected death in epilepsy: assessing the public health burden. Epilepsia. 2014;55:1479–85. PubMed

Hesdorffer DC, Tomson T, Benn E, et al. Do antiepileptic drugs or generalized tonic‐clonic seizure frequency increase SUDEP risk? A combined analysis. Epilepsia. 2012;53:249–52. PubMed

Rheims S, Ryvlin P. Pharmacotherapy for tonic‐clonic seizures. Expert Opin Pharmacother. 2014;15:1417–26. PubMed

Wyllie EE. Treatment of Epilepsy: Principles and Practice. 5th ed Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins; 2011.

Thomas P, Valton L, Genton P. Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain. 2006;129:1281–92. PubMed

Shields WD, Saslow E. Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children. Neurology. 1983;33:1487–9. PubMed

Vendrame M, Khurana DS, Cruz M, et al. Aggravation of seizures and/or EEG features in children treated with oxcarbazepine monotherapy. Epilepsia. 2007;48:2116–20. PubMed

Wechsler RT, French J, Trinka E, et al. Long‐term safety and efficacy outcomes of adjunctive perampanel: an open‐label extension (OLEx) of a phase III study in patients with drug‐resistant primary generalized tonic‐clonic (PGTC) seizures in idiopathic generalized epilepsy (IGE) (P5.233). Neurology. 2017;88(P5):233.

Wechsler RT, French J, Trinka E, et al. Long‐term safety and efficacy of adjunctive perampanel in patients with drug‐resistant primary generalised tonic‐clonic seizures in idiopathic generalised epilepsy: results of an open‐label extension. Epilepsia. 2016;57(S2):168.

De Liso P, Vigevano F, Specchio N, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies—an Italian observational multicenter study. Epilepsy Res. 2016;127:93–100. PubMed

Harden C, Tomson T, Gloss D, et al. Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsy Curr. 2017;17:180–7. PubMed PMC

Hanada T, Hashizume Y, Tokuhara N, et al. Perampanel: a novel, orally active, noncompetitive AMPA‐receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011;52:1331–40. PubMed

Scharfman HE. The neurobiology of epilepsy. Curr Neurol Neurosci Rep. 2007;7:348–54. PubMed PMC

Yamaguchi S, Donevan SD, Rogawski MA. Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res. 1993;15:179–84. PubMed

Seeburg PH. The TINS/TiPS lecture. The molecular biology of mammalian glutamate receptor channels. Trends Neurosci. 1993;16:359–65. PubMed

Di Bonaventura C, Labate A, Maschio M, et al. AMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectives. Expert Opin Pharmacother. 2017;18:1751–64. PubMed

Badawy RAB, Vogrin SJ, Lai A, et al. Capturing the epileptic trait: cortical excitability measures in patients and their unaffected siblings. Brain. 2013;136:1177–91. PubMed

Badawy RAB, Vogrin SJ, Lai A, et al. Patterns of cortical hyperexcitability in adolescent/adult‐onset generalized epilepsies. Epilepsia. 2013;54:871–8. PubMed

Rohracher A, Zimmermann G, Villanueva V, et al. Perampanel in routine clinical use across Europe: pooled, multicenter, observational data. Epilepsia. 2018;59:1727–39. PubMed

Villanueva V, Montoya J, Castillo A, et al. Perampanel in routine clinical use in idiopathic generalized epilepsy: the 12‐month GENERAL study. Epilepsia. 2018;59:1740–52. PubMed

ClinicalTrials.gov . An open‐label extension study to evaluate the safety and tolerability of perampanel (E2007) administered as an adjunctive therapy in epilepsy subjects. Available at: https://clinicaltrials.gov/ct2/show/record/NCT02427607. Accessed May 11, 2020.